• Login
    View Item 
    •   Home
    • 1 Published Research and Commentary
    • TB
    • View Item
    •   Home
    • 1 Published Research and Commentary
    • TB
    • View Item
    Apr 14, 2021
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of MSFTitleAuthorsSubjectsPublisherJournalThis CollectionTitleAuthorsSubjectsPublisherJournal

    Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    Mbuagbaw et al - 2019 - Outcomes ...
    Size:
    1.246Mb
    Format:
    PDF
    Download
    Authors
    Mbuagbaw, L
    Guglielmetti, L
    Hewison, C
    Bakare, N
    Bastard, M
    Caumes, E
    Frechet-Jachym, M
    Robert, J
    Veziris, N
    Khachatryan, N
    Kotrikadze, T
    Hayrapetyan, A
    Avaliani, Z
    Schünemann, HJ
    Lienhardt, C
    Show allShow less
    Issue Date
    2019-05-01
    Submitted date
    2019-05-03
    
    Metadata
    Show full item record
    Journal
    Emerging Infectious Diseases
    Abstract
    Bedaquiline is recommended by the World Health Organization for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data from 5 cohorts of patients treated with bedaquiline in France, Georgia, Armenia, and South Africa and in a multicountry study. The rate of culture conversion to negative at 6 months (by the end of 6 months of treatment) was 78% (95% CI 73.5%-81.9%), and the treatment success rate was 65.8% (95% CI 59.9%-71.3%). Death rate was 11.7% (95% CI 7.0%-19.1%). Up to 91.1% (95% CI 82.2%-95.8%) of the patients experienced >1 adverse event, and 11.2% (95% CI 5.0%-23.2%) experienced a serious adverse event. Lung cavitations were consistently associated with unfavorable outcomes. The use of bedaquiline in MDR and XDR TB treatment regimens appears to be effective and safe across different settings, although the certainty of evidence was assessed as very low.
    Publisher
    Centers for Disease Control and Prevention
    URI
    http://hdl.handle.net/10144/619395
    DOI
    10.3201/eid2505.181823
    PubMed ID
    31002070
    Language
    en
    ISSN
    1080-6059
    ae974a485f413a2113503eed53cd6c53
    10.3201/eid2505.181823
    Scopus Count
    Collections
    TB

    entitlement

    Related articles

    • Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
    • Authors: Bonnet M, Bastard M, du Cros P, Khamraev A, Kimenye K, Khurkhumal S, Hayrapetyan A, Themba D, Telnov A, Sanchez-Padilla E, Hewison C, Varaine F
    • Issue date: 2016 Feb
    • Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
    • Authors: Pym AS, Diacon AH, Tang SJ, Conradie F, Danilovits M, Chuchottaworn C, Vasilyeva I, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, Van Baelen B, van Heeswijk RP, Dannemann B, TMC207-C209 Study Group.
    • Issue date: 2016 Feb
    • Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
    • Authors: Migliori GB, Pontali E, Sotgiu G, Centis R, D'Ambrosio L, Tiberi S, Tadolini M, Esposito S
    • Issue date: 2017 Feb 7
    • Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort.
    • Authors: Guglielmetti L, Le Dû D, Jachym M, Henry B, Martin D, Caumes E, Veziris N, Métivier N, Robert J, MDR-TB Management Group of the French National Reference Center for Mycobacteria and the Physicians of the French MDR-TB Cohort.
    • Issue date: 2015 Jan 15
    • Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    • Authors: Centers for Disease Control and Prevention.
    • Issue date: 2013 Oct 25
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.